Soleno Therapeutics Inc SLNO 深 滬
等待開盤 10-15 09:30:00 美东时间
63.89
-0.380
-0.59%
華盛通- 最 高65.995
- 今 開64.31
- 成交量 89.07万股
- 最 低 63.1646
- 昨 收 64.27
- 總市值 33.70亿
- 52周最高 90.3199
- 市盈率 靜 --
- 換手率 1.69%
- 52周最低 41.50
- 委 比 78.09%
- 總股本 5274.69万
- 歷史最高 90.3199
- 量 比 0.76
- 振 幅 4.40%
- 歷史最低 1.81
- 每 手 1
- 風險率 7.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
New independent director Mark W. Hahn joins Soleno Therapeutics' Board, bringing 30 years of financial leadership experience. Hahn's expertise will support the company's commercial launch of VYKAT™ XR for treating hyperphagia in Prader-Willi syndrome. His background includes successful product launches and financings in the life sciences sector. With his addition, the Board now has seven members. Hahn also serves as Audit Committee Chair for Opte...
10-13 12:00
Soleno Therapeutics, shares are trading higher. Goldman Sachs initiated coverage on the stock and issued a Buy rating.
Soleno Therapeutics, shares are trading higher. Goldman Sachs initiated coverag...
10-08 00:43
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.
09-24 22:05
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental therapy for a rare genetic condition known as Prader-Willi syndrome failed in a ...
09-24 20:05
美股周涨跌榜 | 好莱坞或迎巨震！华纳兄弟探索频道周涨超55%；新思科技绩后暴跌28.9%
好莱坞或迎巨震！华纳兄弟探索频道周涨超55%，传Paramount Skydance拟收购公司；新思科技绩后暴跌28.9%>>
09-13 11:42
Soleno Therapeutics Addresses FDA Adverse Event Report
The latest update is out from Soleno Therapeutics ( ($SLNO) ). Soleno Therapeut...
09-11 00:59
Guggenheim Reiterates Buy on Soleno Therapeutics, Maintains $106 Price Target
Guggenheim analyst Debjit Chattopadhyay reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Buy and maintains $106 price target.
08-27 22:02
Soleno Therapeutics to Participate in Upcoming September Conferences
Soleno Therapeutics will participate in several investor conferences in September 2025, including Cantor Global Healthcare Conference (September 3), Wells Fargo Healthcare Conference (September 4), H.C. Wainwright Global Investment Conference (September 8), Baird Global Healthcare Conference (September 9), and Bernstein Healthcare Forum (September 25). All events will feature Fireside Chat presentations. Replays of the Cantor and Wells Fargo even...
08-27 12:00
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
SAN FRANCISCO, Aug. 20, 2025 /PRNewswire/ -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical ...
08-21 04:02
